Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187132 | 0.76 | HCAR2 (0.49) | GAAHCAR2EPHX2ALDH1A1HRH3 | |
| SCHEMBL10187133 | 0.76 | KCNJ1 (0.51) | GAAHCAR2EPHX2ALDH1A1 | |
| SCHEMBL12195525 | 0.69 | ADORA2A (0.37) | NOS1ALDH1A1DPP4HRH3 | |
| SCHEMBL16644231 | 0.67 | NOS1 (0.34) | NOS1ALDH1A1 | |
| SCHEMBL10312551 | 0.65 | TDO2 (0.38) | HCAR2NOS1ALDH1A1HRH3 | |
| SCHEMBL6799679 | 0.63 | NOS1 (0.41) | GAANOS1ALDH1A1 | |
| SCHEMBL13946247 | 0.63 | NOS1 (0.41) | NOS1ALDH1A1DPP4HRH3 | |
| SCHEMBL10312547 | 0.62 | KCNJ1 (0.51) | ALDH1A1 | |
| SCHEMBL23398990 | 0.62 | GAA (0.56) | GAAEPHX2ALDH1A1 | |
| SCHEMBL2305512 | 0.60 | ALDH1A1 (0.58) | GAANOS1ALDH1A1DPP4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | GAA 1437/4885HCAR2 2/4885NOS1 749/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | GAA 1439/4885HCAR2 2/4885NOS1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.